|
GB9714249D0
(en)
|
1997-07-08 |
1997-09-10 |
Angiogene Pharm Ltd |
Vascular damaging agents
|
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
|
US6720323B2
(en)
|
2000-07-07 |
2004-04-13 |
Angiogene Pharmaceuticals Limited |
Colchinol derivatives as angiogenesis inhibitors
|
|
WO2002004434A1
(en)
*
|
2000-07-07 |
2002-01-17 |
Angiogene Pharmaceuticals Limited |
Colchinol derivatives as vascular damaging agents
|
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
|
EP1438281A4
(en)
|
2001-10-26 |
2006-04-26 |
Oxigene Inc |
FUNCTIONALIZED STILBENE DERIVATIVES USEFUL AS IMPROVED VASCULAR TARGETING AGENTS
|
|
BR0307151A
(pt)
|
2002-02-01 |
2004-12-07 |
Astrazeneca Ab |
Composto ou um sal do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso do composto ou de um seu sal, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, como um ser humano, que necessita de um tratamento do tipo referido, e, processos para a preparação de 5-bromo-7- azaindol, e para a produção de 5-metóxi-7-azaindol
|
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
|
EP1539713B1
(en)
|
2002-08-24 |
2007-12-19 |
Astrazeneca AB |
Pyrimidine derivatives as modulators of chemokine receptor activity
|
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
|
EP1578755B1
(en)
|
2002-12-24 |
2007-08-22 |
AstraZeneca AB |
Phosphonooxy quinazoline derivatives and their pharmaceutical use
|
|
EP1601348A4
(en)
|
2003-02-28 |
2008-12-10 |
Oxigene Inc |
Compositions and methods with improved therapeutic activity
|
|
SE0301010D0
(sv)
|
2003-04-07 |
2003-04-07 |
Astrazeneca Ab |
Novel compounds
|
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
|
BRPI0416692A
(pt)
|
2003-11-19 |
2007-01-30 |
Array Biopharma Inc |
inibidores heterocìclicos de mek e métodos de emprego destes
|
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
|
GB0329771D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Angiogene Pharm Ltd |
Chemical processes & intermediates
|
|
DE602004031777D1
(en)
|
2004-01-05 |
2011-04-21 |
Astrazeneca Ab |
Thiophenderivate als chk-1-inhibitoren
|
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0415320D0
(en)
|
2004-07-08 |
2004-08-11 |
Astrazeneca Ab |
Novel compounds
|
|
KR101280095B1
(ko)
|
2004-08-28 |
2013-09-09 |
아스트라제네카 아베 |
케모킨 수용체 조절제로서의 피리미딘 술폰아미드 유도체
|
|
ATE521638T1
(de)
|
2004-12-21 |
2011-09-15 |
Medimmune Ltd |
Gegen angiopoietin-2 gerichtete antikörper und anwendungen davon
|
|
GB0428100D0
(en)
*
|
2004-12-23 |
2005-01-26 |
Astrazeneca Ab |
Chemical processes & intermediates
|
|
SI1846394T1
(sl)
|
2005-02-04 |
2012-06-29 |
Astrazeneca Ab |
Pirazolilaminopiridinski derivati uporabni kot kinazni inhibitorji
|
|
JP2009501793A
(ja)
|
2005-07-21 |
2009-01-22 |
アストラゼネカ・アクチエボラーグ |
新規ピペリジン誘導体
|
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
|
JPWO2007034917A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規なアデニン化合物
|
|
JPWO2007034916A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
|
JPWO2007034881A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
|
JPWO2007034817A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
|
EP1939199A4
(en)
|
2005-09-22 |
2010-10-20 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
|
US8148572B2
(en)
|
2005-10-06 |
2012-04-03 |
Astrazeneca Ab |
Compounds
|
|
EP1945631B8
(en)
|
2005-10-28 |
2013-01-02 |
AstraZeneca AB |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
|
DE602006009968D1
(de)
|
2005-11-15 |
2009-12-03 |
Array Biopharma Inc |
N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
|
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
|
RU2492185C2
(ru)
|
2005-12-13 |
2013-09-10 |
Астразенека Аб |
Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
|
|
ES2380683T3
(es)
|
2005-12-15 |
2012-05-17 |
Astrazeneca Ab |
Difenil-éteres, -amidas, -sulfuros y - metanos sustituidos para el tratamiento de la enfermedad respiratoria
|
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
|
JP2009538289A
(ja)
|
2006-05-26 |
2009-11-05 |
アストラゼネカ・アクチエボラーグ |
ビアリールまたはヘテロアリール置換インドール
|
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
|
BRPI0715888B1
(pt)
|
2006-08-23 |
2021-11-03 |
Kudos Pharmaceuticals Limited |
Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
|
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
|
CA2672446A1
(en)
|
2006-12-19 |
2008-06-26 |
Astrazeneca Ab |
Quinuclidinol derivatives as muscarinic receptor antagonists
|
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
|
PE20081887A1
(es)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Nuevo compuesto de adenina
|
|
US8044056B2
(en)
|
2007-03-20 |
2011-10-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Adenine compound
|
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
|
EA201000436A1
(ru)
|
2007-10-04 |
2010-10-29 |
Астразенека Аб |
Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
|
|
MX2010003927A
(es)
|
2007-10-11 |
2010-04-30 |
Astrazeneca Ab |
Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
|
|
KR101620539B1
(ko)
|
2007-12-21 |
2016-05-13 |
메디뮨 리미티드 |
인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
|
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
PT2242759E
(pt)
|
2008-02-06 |
2012-12-17 |
Astrazeneca Ab |
Compostos
|
|
ES2401550T3
(es)
|
2008-02-28 |
2013-04-22 |
Merck Patent Gmbh |
Inhibidores de proteína cinasa y uso de los mismos
|
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
SI2297106T1
(sl)
|
2008-05-27 |
2014-09-30 |
Astrazeneca Ab |
Fenoksipiridinilamid derivati in njih uporaba pri zdravljenju PDE4 posredovanih bolezenskih stanj
|
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
|
AU2009324489B2
(en)
|
2008-12-11 |
2015-11-12 |
Axcentua Pharmaceuticals Ab |
Crystalline forms of genistein
|
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
|
US9938268B2
(en)
|
2008-12-17 |
2018-04-10 |
Merck Patent Gmbh |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
|
EP2367822B1
(en)
|
2008-12-18 |
2016-10-05 |
Merck Patent GmbH |
Tricyclic azaindoles
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
US20110053923A1
(en)
|
2008-12-22 |
2011-03-03 |
Astrazeneca |
Chemical compounds 610
|
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
AU2009331528A1
(en)
|
2008-12-23 |
2011-08-11 |
Astrazeneca Ab |
Targeted binding agents directed to alpha5beta1 and uses thereof
|
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
|
SG172986A1
(en)
|
2009-02-10 |
2011-08-29 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
|
EP2483244A1
(en)
|
2009-10-02 |
2012-08-08 |
AstraZeneca AB |
2-pyridone compounds used as inhibitors of neutrophil elastase
|
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
|
BR112012011518B8
(pt)
|
2009-11-18 |
2023-01-10 |
Astrazeneca Ab |
Compostos, composição farmacêutica, kit e usos de um composto
|
|
SI3279215T1
(sl)
|
2009-11-24 |
2020-07-31 |
Medimmune Limited |
Usmerjena vezavna sredstva proti B7-H1
|
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
|
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
|
EA201200863A1
(ru)
|
2009-12-14 |
2013-01-30 |
Мерк Патент Гмбх |
Ингибиторы сфингозинкиназы
|
|
CN102639513A
(zh)
|
2009-12-17 |
2012-08-15 |
默克专利有限公司 |
鞘氨醇激酶抑制剂
|
|
EP3296313B1
(en)
|
2010-01-15 |
2020-12-16 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions, and methods
|
|
RU2012135093A
(ru)
|
2010-01-19 |
2014-03-10 |
Астразенека Аб |
Производные пиразина
|
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
|
US20130059916A1
(en)
|
2010-05-26 |
2013-03-07 |
Stephane Rocchi |
Biguanide compounds and its use for treating cancer
|
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
|
WO2012027957A1
(en)
|
2010-08-28 |
2012-03-08 |
Suzhou Neupharma Co., Ltd. |
Bufalin derivatives, pharmaceutical compositions and use thereof
|
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
|
JP2013542916A
(ja)
|
2010-11-19 |
2013-11-28 |
大日本住友製薬株式会社 |
環状アミド化合物および疾患の処置におけるその使用
|
|
ES2575688T3
(es)
|
2010-12-16 |
2016-06-30 |
Sumitomo Dainippon Pharma Co., Ltd. |
Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
|
|
JP5978226B2
(ja)
|
2010-12-17 |
2016-08-24 |
大日本住友製薬株式会社 |
プリン誘導体
|
|
KR20140003467A
(ko)
|
2010-12-20 |
2014-01-09 |
메디뮨 리미티드 |
항il-18 항체 및 그의 용도
|
|
EP2670763B1
(en)
|
2011-02-02 |
2018-08-01 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions, and methods
|
|
DK2675794T3
(da)
|
2011-02-17 |
2019-05-06 |
Cancer Therapeutics Crc Pty Ltd |
Selektive fak-inhibitorer
|
|
EP2675793B1
(en)
|
2011-02-17 |
2018-08-08 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
UY34013A
(es)
|
2011-04-13 |
2012-11-30 |
Astrazeneca Ab |
?compuestos de cromenona con actividad anti-tumoral?.
|
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
|
CA2841859C
(en)
|
2011-07-12 |
2021-03-09 |
Astrazeneca Ab |
N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio)pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
|
|
EP2736895B1
(en)
|
2011-07-27 |
2016-01-06 |
Astrazeneca AB |
2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
|
|
CN103841828B
(zh)
|
2011-07-29 |
2016-01-13 |
美迪诺亚公司 |
德尼布林二盐酸盐
|
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
|
JP6002223B2
(ja)
|
2011-08-26 |
2016-10-05 |
ニューファーマ， インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
|
EP2753174A4
(en)
|
2011-09-01 |
2015-05-20 |
Xiangping Qian |
PARTICULAR CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
|
|
EP3332785B1
(en)
|
2011-09-14 |
2020-05-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2013043935A1
(en)
|
2011-09-21 |
2013-03-28 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
|
WO2013045955A1
(en)
|
2011-09-29 |
2013-04-04 |
The University Of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
|
US9249111B2
(en)
|
2011-09-30 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-RAF kinase inhibitors
|
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
|
WO2013112950A2
(en)
|
2012-01-25 |
2013-08-01 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP2807161B1
(en)
|
2012-01-28 |
2017-10-04 |
Merck Patent GmbH |
Triazolo[4,5-d]pyrimidine derivatives
|
|
US9045493B2
(en)
|
2012-02-09 |
2015-06-02 |
Merck Patent Gmbh |
Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives
|
|
BR112014019357A8
(pt)
|
2012-02-09 |
2017-07-11 |
Merck Patent Gmbh |
Derivados de tetra-hidro- quinazolinona como inibidores de tanc e parp
|
|
JP6097770B2
(ja)
|
2012-02-21 |
2017-03-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
フロピリジン誘導体
|
|
AU2012370450B2
(en)
|
2012-02-21 |
2017-02-02 |
Merck Patent Gmbh |
Cyclic diaminopyrimidine derivatives
|
|
AU2013224421B2
(en)
|
2012-02-21 |
2017-03-02 |
Merck Patent Gmbh |
8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
|
|
CN104159901B
(zh)
|
2012-03-07 |
2016-10-26 |
默克专利股份公司 |
三唑并吡嗪衍生物
|
|
EA027416B1
(ru)
|
2012-03-28 |
2017-07-31 |
Мерк Патент Гмбх |
Бициклические пиразиноновые производные
|
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
|
PE20142422A1
(es)
|
2012-04-05 |
2015-01-21 |
Hoffmann La Roche |
Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
|
|
US9340570B2
(en)
|
2012-04-29 |
2016-05-17 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2013164061A1
(en)
|
2012-05-04 |
2013-11-07 |
dedeMERCK PATENT GMBH |
Pyrrolotriazinone derivatives
|
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
|
JP6430936B2
(ja)
|
2012-07-24 |
2018-11-28 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
関節症の処置のためのヒドロキシスタチン誘導体
|
|
JP6374384B2
(ja)
|
2012-08-07 |
2018-08-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体
|
|
LT2882714T
(lt)
|
2012-08-08 |
2020-03-10 |
Merck Patent Gmbh |
(azo-)izochinolinono dariniai
|
|
CA2882158A1
(en)
|
2012-08-17 |
2014-02-20 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
|
CN102898330B
(zh)
*
|
2012-09-03 |
2015-02-25 |
浙江大学 |
秋水仙碱衍生物
|
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
|
WO2014047648A1
(en)
|
2012-09-24 |
2014-03-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
SG11201502120XA
(en)
|
2012-09-26 |
2015-04-29 |
Merck Patent Gmbh |
Quinazolinone derivatives as parp inhibitors
|
|
JP6348115B2
(ja)
|
2012-10-26 |
2018-06-27 |
ザ ユニバーシティー オブ クイーンズランド |
がん療法のためのエンドサイトーシス阻害剤および抗体の使用
|
|
US10767229B2
(en)
|
2012-11-05 |
2020-09-08 |
Gmdx Co Pty Ltd |
Methods for determining the cause of somatic mutagenesis
|
|
US9725421B2
(en)
|
2012-11-12 |
2017-08-08 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
|
JP6316835B2
(ja)
|
2012-11-16 |
2018-04-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
３−アミノシクロペンタンカルボキサミド誘導体
|
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
|
DK3381917T3
(da)
|
2013-01-31 |
2021-10-18 |
Bellus Health Cough Inc |
Imidazopyridinforbindelser og anvendelser deraf
|
|
EP2958901B1
(de)
|
2013-02-25 |
2016-11-02 |
Merck Patent GmbH |
2-amino-3,4-dihydro-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren
|
|
EP2964648B1
(en)
|
2013-03-05 |
2016-11-16 |
Merck Patent GmbH |
9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
|
|
EP2972394A4
(en)
|
2013-03-15 |
2016-11-02 |
Sloan Kettering Inst Cancer |
HSP90-DESIGNING AND THERAPY
|
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
|
CN113398147A
(zh)
|
2013-03-15 |
2021-09-17 |
纽罗森特里亚股份有限公司 |
用于癌症的镁组合物及其用途
|
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
|
US20160115146A1
(en)
|
2013-06-07 |
2016-04-28 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
|
WO2014205511A1
(en)
|
2013-06-25 |
2014-12-31 |
University Of Canberra |
Methods and compositions for modulating cancer stem cells
|
|
CA2921410C
(en)
|
2013-08-23 |
2023-03-28 |
Neupharma, Inc. |
Quinazoline derivatives, compositions and their use as kinase inhibitors
|
|
CA2923765C
(en)
|
2013-09-18 |
2021-06-29 |
University Of Canberra |
Stem cell modulation ii
|
|
US20160298197A1
(en)
|
2013-10-01 |
2016-10-13 |
Queensland University Of Technology |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
SG11201701237QA
(en)
|
2014-08-25 |
2017-03-30 |
Univ Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
|
EP3221701B1
(en)
|
2014-11-17 |
2021-03-31 |
The University of Queensland |
Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
|
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
|
EP3270694A4
(en)
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
|
CN108349964B
(zh)
|
2015-08-04 |
2021-06-01 |
常州千红生化制药股份有限公司 |
N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物
|
|
ES2873841T3
(es)
|
2015-08-26 |
2021-11-04 |
Gmdx Co Pty Ltd |
Métodos para detectar la recurrencia del cáncer
|
|
KR20180095694A
(ko)
|
2015-12-23 |
2018-08-27 |
퀸스랜드 유니버시티 오브 테크놀로지 |
핵산 올리고머 및 이의 용도
|
|
US10487115B2
(en)
|
2016-02-01 |
2019-11-26 |
University Of Canberra |
Proteinaceous compounds and uses therefor
|
|
KR102830910B1
(ko)
|
2016-02-15 |
2025-07-04 |
아스트라제네카 에이비이 |
세디라닙의 고정된 간헐적 투약을 포함하는 방법
|
|
DK3442535T3
(da)
|
2016-04-15 |
2022-09-05 |
Cancer Research Tech Ltd |
Heterocykliske stoffer som as ret-kinase-hæmmere
|
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
JP6985388B2
(ja)
|
2016-07-29 |
2021-12-22 |
ラプト・セラピューティクス・インコーポレイテッド |
ケモカイン受容体調節剤及びそれの使用
|
|
EP3497087B1
(en)
|
2016-08-15 |
2021-11-10 |
Neupharma, Inc. |
Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer
|
|
WO2018055402A1
(en)
|
2016-09-22 |
2018-03-29 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
|
MX387236B
(es)
|
2016-12-05 |
2025-03-18 |
Apros Therapeutics Inc |
Compuestos de pirimidina que contienen grupos ácidos
|
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
|
US11111245B2
(en)
|
2017-02-01 |
2021-09-07 |
Aucentra Therapeutics Pty Ltd |
Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
|
US10703723B2
(en)
|
2017-03-09 |
2020-07-07 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
|
EP4371562A3
(en)
|
2017-05-26 |
2024-08-14 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
|
WO2018215801A1
(en)
|
2017-05-26 |
2018-11-29 |
Cancer Research Technology Limited |
Benzimidazolone derived inhibitors of bcl6
|
|
ES2897200T3
(es)
|
2017-05-31 |
2022-02-28 |
Amplio Pharma Ab |
Una composición farmacéutica que comprende una combinación de metotrexato y novobiocina, y el uso de la composición en terapia
|
|
WO2019007447A1
(en)
|
2017-07-05 |
2019-01-10 |
E.P.O.S Iasis Research And Development Limited |
MULTIFUNCTIONAL CONJUGATES
|
|
FI3661941T3
(fi)
|
2017-08-01 |
2023-03-23 |
Merck Patent Gmbh |
Tiatsolopyridiinijohdannaisia adenosiinireseptoriantagonisteina
|
|
WO2019034890A1
(en)
|
2017-08-18 |
2019-02-21 |
Cancer Research Technology Limited |
PYRROLO [2,3-B] PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
|
|
EP3672952B1
(en)
|
2017-08-21 |
2022-12-14 |
Merck Patent GmbH |
Benzimidazole derivatives as adenosine receptor antagonists
|
|
AU2018320672B2
(en)
|
2017-08-21 |
2023-09-07 |
Merck Patent Gmbh |
Quinoxaline derivatives as adenosine receptor antagonists
|
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
|
AU2018360766B2
(en)
|
2017-11-06 |
2024-09-19 |
Rapt Therapeutics, Inc. |
Anticancer agents
|
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
|
ES2965337T3
(es)
|
2017-11-23 |
2024-04-12 |
Medac Ges Fuer Klinische Spezialpraeparate Mbh |
Composición farmacéutica para administración oral que contiene sulfasalazina y/o una sal orgánica de sulfasalazina, proceso de producción y uso
|
|
WO2019136514A1
(en)
|
2018-01-15 |
2019-07-18 |
University Of South Australia |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
|
IL276295B2
(en)
|
2018-01-26 |
2024-02-01 |
Rapt Therapeutics Inc |
Modulators of chemokine receptors and their uses
|
|
WO2019157225A2
(en)
|
2018-02-08 |
2019-08-15 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
|
SG11202009735QA
(en)
|
2018-04-13 |
2020-10-29 |
Cancer Research Tech Ltd |
Bcl6 inhibitors
|
|
BR112020024062A2
(pt)
|
2018-04-27 |
2021-02-09 |
Spruce Biosciences, Inc. |
métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
|
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
|
US10857153B2
(en)
|
2018-06-04 |
2020-12-08 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups
|
|
US11046699B2
(en)
|
2018-06-05 |
2021-06-29 |
Rapt Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
|
PL4360713T3
(pl)
|
2018-09-18 |
2025-06-23 |
F. Hoffmann-La Roche Ag |
Pochodne chinazoliny jako leki przeciwnowotworowe
|
|
WO2020068600A1
(en)
|
2018-09-24 |
2020-04-02 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
|
|
ES2960883T3
(es)
|
2018-10-25 |
2024-03-07 |
Merck Patent Gmbh |
Derivados de 5-azaindazol como antagonistas de los receptores de adenosina
|
|
BR112021007727A2
(pt)
|
2018-10-25 |
2021-07-27 |
Merck Patent Gmbh |
derivados de 5-azaindazol como antagonistas receptores de adenosina
|
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
|
EP3960858B1
(en)
|
2018-12-25 |
2025-05-07 |
Beijing Baishihekang Pharmaceutical Technology (BSJpharma) Co., Ltd. |
Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
|
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
|
WO2021111124A1
(en)
|
2019-12-02 |
2021-06-10 |
Storm Therapeutics Limited |
Polyheterocyclic compounds as mettl3 inhibitors
|
|
CA3131312A1
(en)
|
2019-02-25 |
2020-09-03 |
Bellus Health Cough Inc. |
Treatment with p2x3 modulators
|
|
CN113795483B
(zh)
|
2019-03-07 |
2024-12-31 |
默克专利有限公司 |
作为shp2拮抗剂的甲酰胺-嘧啶衍生物
|
|
WO2020191448A1
(en)
|
2019-03-28 |
2020-10-01 |
Amplia Therapeutics Limited |
A salt and crystal form of a fak inhibitor
|
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
|
KR20210144844A
(ko)
|
2019-03-29 |
2021-11-30 |
아스트라제네카 아베 |
비-소세포 폐암의 치료에 사용하기 위한 오시머티닙
|
|
US12358915B2
(en)
|
2019-04-05 |
2025-07-15 |
STORM Therapeutics Ltd. |
METTL3 inhibitory compounds
|
|
WO2020210384A1
(en)
|
2019-04-08 |
2020-10-15 |
Merck Patent Gmbh |
Pyrimidinone derivatives as shp2 antagonists
|
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
|
KR20220054840A
(ko)
|
2019-08-31 |
2022-05-03 |
이턴 바이오파마 (상하이) 코., 엘티디. |
Fgfr 억제제용 피라졸류 유도체 및 이의 제조방법
|
|
CA3147493A1
(en)
|
2019-09-20 |
2021-03-25 |
Jr. James Clifford Sutton |
4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
|
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
|
US20230183197A1
(en)
|
2020-06-01 |
2023-06-15 |
Neophore Limited |
Inhibitors of mlh1 and/or pms2 for cancer treatment
|
|
GB202012482D0
(en)
|
2020-08-11 |
2020-09-23 |
Univ Of Huddersfield |
Novel compounds and therapeutic uses thereof
|
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
|
WO2022074391A1
(en)
|
2020-10-08 |
2022-04-14 |
Storm Therapeutics Limited |
Compounds inhibitors of mettl3
|
|
US12030888B2
(en)
|
2021-02-24 |
2024-07-09 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
|
WO2022233718A2
(en)
|
2021-05-03 |
2022-11-10 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
|
BR112023024040A2
(pt)
|
2021-05-17 |
2024-02-06 |
Hk Inno N Corp |
Composto, o isômero óptico do mesmo, o solvato do mesmo, o hidrato do mesmo ou o sal farmaceuticamente aceitável do mesmo e seu uso, composição farmacêutica que compreende o dito composto, composição de alimento funcional para a saúde e preparação combinada
|
|
CA3221411A1
(en)
|
2021-05-25 |
2022-12-01 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
|
GB202110373D0
(en)
|
2021-07-19 |
2021-09-01 |
Neophore Ltd |
Inhibitor compounds
|
|
IT202100023357A1
(it)
|
2021-09-09 |
2023-03-09 |
Cheirontech S R L |
Peptidi con attività anti-angiogenica
|
|
US20250002491A1
(en)
|
2021-10-04 |
2025-01-02 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
|
WO2023057389A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
|
GB202117224D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Inhibitor compounds
|
|
GB202117225D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Protac compounds
|
|
IL314200A
(en)
|
2022-01-10 |
2024-09-01 |
Merck Patent Gmbh |
Heterocycles are being converted as HSET inhibitors
|
|
GB202202006D0
(en)
|
2022-02-15 |
2022-03-30 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Anti-cancer treatment
|
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
|
US12240837B2
(en)
|
2022-04-06 |
2025-03-04 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
|
CN119562945A
(zh)
|
2022-05-11 |
2025-03-04 |
癌症研究技术有限公司 |
Ikk抑制剂
|
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
|
EP4565592A1
(en)
|
2022-08-01 |
2025-06-11 |
Neupharma, Inc. |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
|
EP4612149A1
(en)
|
2022-11-02 |
2025-09-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
|
EP4615838A1
(en)
|
2022-11-07 |
2025-09-17 |
Merck Patent GmbH |
Substituted bi-and tricyclic hset inhibitors
|
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
GB202300881D0
(en)
|
2023-01-20 |
2023-03-08 |
Neophore Ltd |
Inhibitor compounds
|
|
WO2024173530A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
|
|
WO2024173514A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Amide and ester-substituted imidazopyridine compounds
|
|
WO2024173453A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted imidazopyridine compounds
|
|
WO2024173524A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted benzimidazole compounds
|
|
US12162895B2
(en)
|
2023-03-10 |
2024-12-10 |
Breakpoint Therapeutics Gmbh |
DNA polymerase theta inhibitor for treatment of cancer
|
|
WO2024209035A1
(en)
|
2023-04-05 |
2024-10-10 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
|
GB202306601D0
(en)
|
2023-05-04 |
2023-06-21 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
|
GB202307924D0
(en)
|
2023-05-26 |
2023-07-12 |
Neophore Ltd |
Inhibitor compounds
|
|
GB2631509A
(en)
|
2023-07-04 |
2025-01-08 |
Univ Liverpool |
Compositions
|
|
GB2631507A
(en)
|
2023-07-04 |
2025-01-08 |
Univ Liverpool |
Compositions
|
|
WO2025046148A1
(en)
|
2023-09-01 |
2025-03-06 |
Forx Therapeutics Ag |
Novel parg inhibitors
|
|
WO2025056923A1
(en)
|
2023-09-15 |
2025-03-20 |
Cambridge Enterprise Limited |
Combination therapy
|
|
WO2025073792A1
(en)
|
2023-10-02 |
2025-04-10 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
GB202315149D0
(en)
|
2023-10-03 |
2023-11-15 |
Celleron Therapeutics Ltd |
Combination therapy
|
|
WO2025073870A1
(en)
|
2023-10-03 |
2025-04-10 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
|
GB202316595D0
(en)
|
2023-10-30 |
2023-12-13 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
GB202316683D0
(en)
|
2023-10-31 |
2023-12-13 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025093755A1
(en)
|
2023-11-01 |
2025-05-08 |
Forx Therapeutics Ag |
Novel parc inhibitors
|
|
GB202317368D0
(en)
|
2023-11-13 |
2023-12-27 |
Breakpoint Therapeutics Gmbh |
Novel compounds, compositions and therapeutic uses thereof
|
|
WO2025104443A1
(en)
|
2023-11-14 |
2025-05-22 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025114480A1
(en)
|
2023-11-28 |
2025-06-05 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
WO2025136811A1
(en)
|
2023-12-18 |
2025-06-26 |
Ideaya Biosciences, Inc. |
Chemical compounds and uses thereof
|
|
GB202319863D0
(en)
|
2023-12-21 |
2024-02-07 |
Breakpoint Therapeutics Gmbh |
Movel compounds, compositions and therapeutics uses thereof
|
|
GB202319864D0
(en)
|
2023-12-21 |
2024-02-07 |
Breakpoint Therapeutics Gmbh |
Novel compounds, compositions and therapeutic uses thereof
|
|
WO2025133395A1
(en)
|
2023-12-22 |
2025-06-26 |
Forx Therapeutics Ag |
Bicyclic (hetero)arylene wrn inhibitory compounds
|
|
WO2025133396A1
(en)
|
2023-12-22 |
2025-06-26 |
Forx Therapeutics Ag |
Novel bicyclo heteroaryl parg inhibitors
|
|
WO2025191176A1
(en)
|
2024-03-14 |
2025-09-18 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
WO2025194036A1
(en)
*
|
2024-03-14 |
2025-09-18 |
Washington University |
Autophagy enhancers
|
|
NL2037411B1
(en)
|
2024-04-08 |
2025-10-31 |
Univ Leiden |
Protac compounds
|
|
GB202407738D0
(en)
|
2024-05-31 |
2024-07-17 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025262192A1
(en)
|
2024-06-21 |
2025-12-26 |
Breakpoint Therapeutics Gmbh |
Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors
|
|
WO2026003380A1
(en)
|
2024-06-28 |
2026-01-02 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|